A higher Alzheimer’s disease polygenic risk score is associated with faster cognitive decline in people with mild cognitive impairment or Alzheimer’s disease dementia, according to a study by Ace Alzheimer Center Barcelona with data from 8,096 participants. However, the score’s added predictive value over standard clinical and sociodemographic variables is limited.
Berta Calm, a researcher at Ace Alzheimer Center Barcelona, is the first author of an analysis of data from more than 8,000 people with mild cognitive impairment or Alzheimer’s disease dementia.
The study, published in The Journal of Prevention of Alzheimer’s Disease, examines whether the Alzheimer’s disease polygenic risk score (AD-PRS) provides information on the rate of cognitive decline in people who already have mild cognitive impairment or Alzheimer’s disease dementia.
The work brings together the expertise of the Artificial Intelligence Programme and the Genomics Programme at Ace Alzheimer Center Barcelona. It also uses data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) as an external cohort to assess how well the predictive models generalise.
What is the Alzheimer’s disease polygenic risk score?
The polygenic risk score combines information from multiple genetic variants associated with susceptibility to Alzheimer’s disease. The aim of this score is to summarise part of a person’s genetic predisposition to the disease in a single measure, without amounting to an individual probability of developing it.
To study the relationship between this score and cognitive progression, the research team analysed longitudinal data from 7,233 patients seen at Ace and 863 ADNI participants.
How is polygenic risk related to cognitive decline?
The results show that a higher polygenic risk score is associated with faster cognitive decline. The association remains even after adjusting for clinical and sociodemographic variables and for APOE genotype, one of the main genetic risk factors for Alzheimer’s disease.
The team assessed global cognitive progression using the Mini-Mental State Examination (MMSE), as well as changes across different cognitive domains. It also applied machine learning techniques to explore what information the genetic variants included in the score provided, alongside factors such as age and education.
Can genetic risk predict how a person with Alzheimer’s disease will progress?
Not yet, at least not accurately enough to be used on its own for individual prediction.
Although the study identifies a consistent association between a higher polygenic risk score and the rate of decline, adding this score to standard clinical and sociodemographic variables improves prediction only modestly.
The polygenic risk score can therefore help explain why cognitive progression varies from one person to another, but it cannot, on its own, anticipate how a specific individual will progress.
Why does the relationship between polygenic risk and cognitive decline matter?
The study improves our understanding of the role of genetics in the differences in progression between patients with Alzheimer’s disease and provides evidence to support further research into models that integrate genetic and clinical information.
Alongside Berta Calm, the authors include Sergi Valero, Agustín Ruiz and other researchers from Ace Alzheimer Center Barcelona.
Scientific article: Predictive value of the Alzheimer polygenic risk score on cognitive decline in patients with mild cognitive impairment and Alzheimer’s disease dementia
